Agilon Health (NYSE:AGL) Releases Quarterly Earnings Results, Misses Expectations By $0.19 EPS

Agilon Health (NYSE:AGL) posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.19), Zacks reports. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.46 billion. Agilon Health had a negative net margin of 6.60% and a negative return on equity of 120.82%.

Here are the key takeaways from Agilon Health’s conference call:

• 2026 guidance: Management expects revenue around $5.5B (midpoint), medical margin ~$325M and adjusted EBITDA roughly breakeven at the midpoint, with platform membership targeted at 525k–540k (MA ~430k, ACO ~103k) and a net cost-trend assumption near 7%.
• Operational progress includes an enhanced data pipeline (member-level risk scoring covering >85% of members), AI-assisted Burden of Illness identification, and clinical pathways (CHF active in >90% of the network) that management says will improve risk capture, utilization and quality.
• 2025 financials were weak—full-year adjusted EBITDA of -$296M and medical margin of -$57M—driven by elevated cost trends (~6.5%) and several large inpatient claims, leading the company to exit unprofitable payer contracts and reduce MA membership (to ~430k, including ~25k on care-coordination fee arrangements).
• Liquidity and policy outlook: year-end cash of $285M (plus $91M ACO-held cash) with an extended credit facility and a plan to finish 2026 with at least $125M, while management warns the CMS Advance Notice may understate cost trends but believes its BOI/clinical initiatives can mitigate much of the risk-model impact.

Agilon Health Stock Performance

Shares of AGL opened at $0.33 on Tuesday. The company has a market cap of $135.25 million, a PE ratio of -0.34 and a beta of 0.11. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average price of $0.59 and a 200-day moving average price of $0.75. Agilon Health has a 12-month low of $0.30 and a 12-month high of $6.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in Agilon Health by 196.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock valued at $13,812,000 after purchasing an additional 13,283,930 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of Agilon Health by 1,346.6% in the 4th quarter. AQR Capital Management LLC now owns 10,211,767 shares of the company’s stock worth $7,033,000 after purchasing an additional 9,505,837 shares in the last quarter. Voleon Capital Management LP boosted its holdings in shares of Agilon Health by 5,519.2% in the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company’s stock worth $2,823,000 after purchasing an additional 2,692,259 shares in the last quarter. Millennium Management LLC increased its position in shares of Agilon Health by 280.4% during the 3rd quarter. Millennium Management LLC now owns 2,998,838 shares of the company’s stock valued at $3,089,000 after purchasing an additional 2,210,568 shares during the last quarter. Finally, Amundi bought a new position in shares of Agilon Health during the 4th quarter valued at about $1,356,000.

Analyst Ratings Changes

Several brokerages have commented on AGL. BTIG Research restated a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, December 3rd. Citigroup lowered their price target on shares of Agilon Health from $21.25 to $18.75 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Barclays cut their price objective on shares of Agilon Health from $25.00 to $12.50 and set an “underweight” rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Agilon Health presently has a consensus rating of “Hold” and a consensus target price of $54.38.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.